PMV Pharmaceuticals PMVP has gained nearly 19% in the past three months, primarily due to encouraging clinical data for its lead drug candidate, rezatapopt, and progress toward a potential regulatory filing in ovarian cancer.
Positive Ovarian Cancer Data Drive PMVP’s Growth
PMV Pharmaceuticals’ key growth driver is rezatapopt, an investigational precision oncology drug being developed to treat cancers harboring a specific mutation called TP53 Y220C.
In August, the company announced updated interim data from the phase II pivotal portion of the ongoing PYNNACLE study evaluating rezatapopt monotherapy in patients with platinum-resistant/refractory ovarian cancer carrying the TP53 Y220C mutation.
The study data demonstrated that treatment with rezatapopt led to an overall response rate of 46% among 76 evaluable patients, including four confirmed complete responses and 29 confirmed partial responses. The median duration of response was 10 months among patients with confirmed responses. Rezatapopt continued to show a favorable safety profile, with most treatment-related side effects being mild to moderate.
The results highlight rezatapopt’s potential to address an unmet medical need in ovarian cancer and strengthen investor confidence in the candidate’s development prospects.
Year to date, shares of PMV Pharmaceuticals have risen 21.6% against the industry’s 4.5% decline.
Image Source: Zacks Investment Research
The phase II portion of the PYNNACLE study is designed to evaluate rezatapopt across five patient cohorts covering ovarian, lung, breast and endometrial cancers, along with other solid tumors.
Following discussions with the FDA, the company remains on track to seek accelerated approval of rezatapopt for platinum-resistant or refractory ovarian cancer. The company plans to submit a new drug application (NDA) in the first quarter of 2027.
PMV Pharmaceuticals expects to present an update covering all phase II pivotal study cohorts at a medical conference in the fourth quarter of 2026, including the primary analysis results from the ovarian cancer cohort.
The upcoming data presentation could further clarify rezatapopt’s efficacy and support the company’s regulatory plans. However, the filing timeline and potential approval remain subject to clinical results, execution and regulatory review.
PMV Pharmaceuticals, Inc. Price and Consensus
PMV Pharmaceuticals, Inc. price-consensus-chart | PMV Pharmaceuticals, Inc. Quote
Public Offering Strengthens PMVP’s Financial Position
The company is strengthening its financial position to support rezatapopt’s continued development. On Aug. 31, 2026, the company priced a public offering expected to generate approximately $50.8 million in gross proceeds.
PMV Pharmaceuticals expects its existing cash resources and proceeds from the offering to fund operations into the first quarter of 2028, excluding any proceeds from warrant exercises.
The additional funding should help the company advance rezatapopt toward its planned NDA submission and support other development activities.
PMVP's Zacks Rank & Other Stocks to Consider
PMV Pharmaceuticals currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Amarin AMRN and Corcept Therapeutics CORT, currently sporting a Zacks Rank #1 (Strong Buy) each and Aldeyra Therapeutics ALDX, carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have surged 248.2% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one while meet in the remaining occasion with the average surprise being 240.74%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 41.5% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 82.3% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PMV Pharmaceuticals, Inc. (PMVP): Free Stock Analysis Report
Amarin Corporation PLC (AMRN): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
Aldeyra Therapeutics, Inc. (ALDX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).